RxSight, Inc. Research and Development Expense
RxSight, Inc. (RXST) reported Research and Development Expense of $9.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- RxSight, Inc. research and development expense for the quarter ending 2026-06-30 was $9.24M, a 9.59% decline year-over-year.
- RxSight, Inc. research and development expense for the quarter ending 2026-03-31 was $9.47M, a 8.63% decline year-over-year.
- RxSight, Inc. research and development expense for the quarter ending 2025-12-31 was $8.90M, a 3.28% decline year-over-year.
- RxSight, Inc. research and development expense for the quarter ending 2025-09-30 was $9.06M, a 2.51% increase year-over-year.
- RxSight, Inc. research and development expense for fiscal 2025 was $38.55M, a 12.17% increase from fiscal 2024.
- RxSight, Inc. research and development expense for fiscal 2024 was $34.37M, a 18.30% increase from fiscal 2023.
- RxSight, Inc. research and development expense for fiscal 2023 was $29.05M, a 11.82% increase from fiscal 2022.
- RxSight, Inc. research and development expense for fiscal 2022 was $25.98M, a 6.05% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.24M 10-Q · filed 2026-08-05 | $18.71M 10-Q · filed 2026-08-05 | $27.61M derived: sum of 3 quarters · filed 2026-08-05 | $36.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $9.47M 10-Q · filed 2026-05-06 | $18.38M derived: sum of 2 quarters · filed 2026-05-06 | $27.44M derived: sum of 3 quarters · filed 2026-05-06 | $37.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $8.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $17.96M derived: sum of 2 quarters · filed 2026-02-25 | $28.18M derived: sum of 3 quarters · filed 2026-08-05 | $38.55M 10-K · filed 2026-02-25 |
| 2025-09-30 | $9.06M 10-Q · filed 2025-11-05 | $19.28M derived: sum of 2 quarters · filed 2026-08-05 | $29.64M 10-Q · filed 2025-11-05 | $38.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $10.22M 10-Q · filed 2026-08-05 | $20.58M 10-Q · filed 2026-08-05 | $29.79M derived: sum of 3 quarters · filed 2026-08-05 | $38.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.37M 10-Q · filed 2026-05-06 | $19.57M derived: sum of 2 quarters · filed 2026-05-06 | $28.41M derived: sum of 3 quarters · filed 2026-05-06 | $36.70M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $18.05M derived: sum of 2 quarters · filed 2026-02-25 | $26.34M derived: sum of 3 quarters · filed 2026-02-25 | $34.37M 10-K · filed 2026-02-25 |
| 2024-09-30 | $8.84M 10-Q · filed 2025-11-05 | $17.13M derived: sum of 2 quarters · filed 2025-11-05 | $25.16M 10-Q · filed 2025-11-05 | $32.50M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $8.29M 10-Q · filed 2025-08-07 | $16.32M 10-Q · filed 2025-08-07 | $23.66M derived: sum of 3 quarters · filed 2026-02-25 | $30.76M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $8.03M 10-Q · filed 2025-05-07 | $15.37M derived: sum of 2 quarters · filed 2026-02-25 | $22.47M derived: sum of 3 quarters · filed 2026-02-25 | $29.87M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $14.44M derived: sum of 2 quarters · filed 2026-02-25 | $21.84M derived: sum of 3 quarters · filed 2026-02-25 | $29.05M 10-K · filed 2026-02-25 |
| 2023-09-30 | $7.10M 10-Q · filed 2024-11-07 | $14.50M derived: sum of 2 quarters · filed 2024-11-07 | $21.71M 10-Q · filed 2024-11-07 | $28.39M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $7.40M 10-Q · filed 2024-08-05 | $14.61M 10-Q · filed 2024-08-05 | $21.29M derived: sum of 3 quarters · filed 2025-02-25 | $27.68M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $7.21M 10-Q · filed 2024-05-06 | $13.89M derived: sum of 2 quarters · filed 2025-02-25 | $20.28M derived: sum of 3 quarters · filed 2025-02-25 | $26.47M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $13.07M derived: sum of 2 quarters · filed 2025-02-25 | $19.26M derived: sum of 3 quarters · filed 2025-02-25 | $25.98M 10-K · filed 2025-02-25 |
| 2022-09-30 | $6.39M 10-Q · filed 2023-11-09 | $12.58M derived: sum of 2 quarters · filed 2023-11-09 | $19.30M 10-Q · filed 2023-11-09 | $25.21M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $6.19M 10-Q · filed 2023-08-07 | $12.91M 10-Q · filed 2023-08-07 | $18.83M derived: sum of 3 quarters · filed 2023-08-07 | $24.20M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $6.72M 10-Q · filed 2023-05-09 | $12.63M derived: sum of 2 quarters · filed 2023-05-09 | $18.01M derived: sum of 3 quarters · filed 2023-05-09 | $24.57M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $11.29M derived: sum of 2 quarters · filed 2023-03-06 | $17.86M derived: sum of 3 quarters · filed 2023-03-06 | $24.50M 10-K · filed 2023-03-06 |
| 2021-09-30 | $5.38M 10-Q · filed 2022-11-07 | $11.94M derived: sum of 2 quarters · filed 2022-11-07 | $18.58M 10-Q · filed 2022-11-07 | $23.86M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $6.56M 10-Q · filed 2022-08-08 | $13.21M 10-Q · filed 2022-08-08 | $18.48M derived: sum of 3 quarters · filed 2022-08-08 | $24.28M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $6.64M 10-Q · filed 2022-05-05 | $11.91M derived: sum of 2 quarters · filed 2022-05-05 | $17.72M derived: sum of 3 quarters · filed 2022-05-05 | $22.80M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $11.07M derived: sum of 2 quarters · filed 2022-03-08 | $16.16M derived: sum of 3 quarters · filed 2022-03-08 | $21.93M 10-K · filed 2022-03-08 |
| 2020-09-30 | $5.80M 10-Q · filed 2021-11-10 | $10.88M derived: sum of 2 quarters · filed 2021-11-10 | $16.66M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.08M 10-Q · filed 2021-09-09 | $10.86M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |